Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Rare Diseases 1Neuromyelitis Optica 1Neurologic Manifestations 1Myelitis, Transverse 1Multiple Sclerosis 1Mental Disorders 1Encephalomyelitis, Acute Disseminated 1Diffuse Cerebral Sclerosis of Schilder 1

Interventions

Radiotherapy 106Cyclophosphamide 97Cisplatin 75Carboplatin 66Fluorouracil 64Etoposide 61Doxorubicin 60Chemotherapy, Adjuvant 60Vincristine 56Peripheral Blood Stem Cell Transplantation 48Filgrastim 47Paclitaxel 46Gemcitabine 44Cytarabine 41Neoadjuvant Therapy 40Leucovorin 40Docetaxel 35Melphalan 31Oxaliplatin 29Methotrexate 29Ifosfamide 25Gene Expression Profiling 25Amplified Fragment Length Polymorphism Analysis 24Immunohistochemistry 23Dexamethasone 22Irinotecan 21aldesleukin 20Prednisolone 20Interferon-alpha 20Tamoxifen 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × NIH × Plasma Exchange × Clear all
NCT00004645 2005-06-24

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone

Office of Rare Diseases (ORD)

Phase 3 Unknown
22 enrolled

Mental Disorders, Diffuse Cerebral Sclerosis of Schilder, Encephalomyelitis, Acute Disseminated, Multiple Sclerosis, Myelitis, Transverse, Neurologic Manifestations, Neuromyelitis Optica, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡